Assessment of the Impact of L-Thyroxine Therapy on Bleeding Risk in Patients Receiving Vitamin K Antagonists

Overview

Journal Clin Drug Investig

Date 2017 Jun 15

PMID 28612237

Authors

Fares Moustafa

Remi Malhomme

Bruno Pereira

Alain Barres

Jennifer Saint-Denis

Frederic Dutheil

Marie Batisse

Jeannot Schmidt

Affiliations

Soon will be listed here.

Abstract

Background: Several studies have suggested a link exists between L-thyroxine and the coagulation system, and, according to some drug interaction studies, L-thyroxine can potentiate the effect of warfarin. This study sought to assess whether thyroid hormone therapy could impact the risk of bleeding in patients receiving vitamin K antagonists (VKAs).

Methods: We conducted a monocentric, retrospective study on prospectively collected data from consecutive patients enrolled in the Registry of patient with AntiThrombotic agents admitted to an Emergency Department (RATED) database, and compared the hemorrhage rates (both major and nonmajor) of patients receiving treatment with and without L-thyroxine. Propensity score matching analysis was performed to reduce the differences between patients receiving L-thyroxine and those not receiving L-thyroxine in order to reassess bleeding outcomes in patients receiving VKAs.

Results: From January 2014 to June 2015, 1454 patients receiving VKAs were recruited into the RATED database. Overall, 187 patients (12.8%) received L-thyroxine. Patients receiving L-thyroxine were more likely to be female than those not receiving L-thyroxine (78.1 vs. 55%) and more likely to exhibit hypertension (65.5 vs. 55.7%; p = 0.015), but less likely to have history of myocardial infarction (9.6 vs. 16.6%; p = 0.022) or higher creatinine levels (96.1 vs. 112.1 μmol/L; p = 0.04). After propensity score matching, bleeding outcomes were not significantly different between patients receiving L-thyroxine and those not receiving L-thyroxine.

Conclusions: Our study revealed no evidence that L-thyroxine could increase bleeding risk in patients receiving VKAs. However, physicians must be aware that patients with thyroid disease receiving VKA therapy could have other drug interactions, particularly with amiodarone therapy. CLINICALTRIALS.

Gov Number: NCT02706080.

References

Squizzato A, Romualdi E, Buller H, Gerdes V . Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab. 2007; 92(7):2415-20. DOI: 10.1210/jc.2007-0199. View

Guyatt G, Akl E, Crowther M, Gutterman D, Schuunemann H . Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):7S-47S. PMC: 3278060. DOI: 10.1378/chest.1412S3. View

Yango J, Alexopoulou O, Eeckhoudt S, Hermans C, Daumerie C . Evaluation of the respective influence of thyroid hormones and TSH on blood coagulation parameters after total thyroidectomy. Eur J Endocrinol. 2011; 164(4):599-603. DOI: 10.1530/EJE-10-0837. View

Debeij J, Cannegieter S, van Zaane B, van Zanten A, Rosendaal F, Gerdes V . Major Haemorrhage during Vitamin K Antagonist Treatment: The Influence of Thyroid Hormone Levels. Eur Thyroid J. 2014; 3(1):32-7. PMC: 4005261. DOI: 10.1159/000357578. View

Lloyd-Jones D, Adams R, Brown T, Carnethon M, Dai S, de Simone G . Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010; 121(7):948-54. DOI: 10.1161/CIRCULATIONAHA.109.192666. View

Meegaard P, Holck L, Pottegard A, Madsen H, Hallas J . Excessive anticoagulation with warfarin or phenprocoumon may have multiple causes. Dan Med J. 2012; 59(2):A4383. View

Kuijer P, Hutten B, Prins M, Buller H . Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999; 159(5):457-60. DOI: 10.1001/archinte.159.5.457. View

Hart R, Pearce L, Aguilar M . Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857-67. DOI: 10.7326/0003-4819-146-12-200706190-00007. View

Kurnik D, Loebstein R, Farfel Z, Ezra D, Halkin H, Olchovsky D . Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore). 2004; 83(2):107-113. DOI: 10.1097/01.md.0000123095.65294.34. View

10.

Beyth R, Quinn L, Landefeld C . Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998; 105(2):91-9. DOI: 10.1016/s0002-9343(98)00198-3. View

11.

Klok F, Hosel V, Clemens A, Yollo W, Tilke C, Schulman S . Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J. 2016; 48(5):1369-1376. DOI: 10.1183/13993003.00280-2016. View

12.

Becattini C, Franco L, Beyer-Westendorf J, Masotti L, Nitti C, Vanni S . Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. Int J Cardiol. 2016; 227:261-266. DOI: 10.1016/j.ijcard.2016.11.117. View

13.

Holbrook A, Pereira J, Labiris R, McDonald H, Douketis J, Crowther M . Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165(10):1095-106. DOI: 10.1001/archinte.165.10.1095. View

14.

Austin P, Small D . The use of bootstrapping when using propensity-score matching without replacement: a simulation study. Stat Med. 2014; 33(24):4306-19. PMC: 4260115. DOI: 10.1002/sim.6276. View

15.

Homoncik M, Gessl A, Ferlitsch A, Jilma B, Vierhapper H . Altered platelet plug formation in hyperthyroidism and hypothyroidism. J Clin Endocrinol Metab. 2007; 92(8):3006-12. DOI: 10.1210/jc.2006-2644. View

16.

Jobski K, Behr S, Garbe E . Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database. Eur J Clin Pharmacol. 2011; 67(9):941-51. DOI: 10.1007/s00228-011-1031-6. View

17.

Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G . Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab. 2001; 86(2):732-7. DOI: 10.1210/jcem.86.2.7221. View

18.

Palareti G, Cosmi B . Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost. 2009; 102(2):268-78. DOI: 10.1160/TH08-11-0730. View

19.

Hollowell J, Staehling N, Flanders W, Hannon W, Gunter E, Spencer C . Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87(2):489-99. DOI: 10.1210/jcem.87.2.8182. View

20.

Rubboli A, Becattini C, Verheugt F . Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol. 2011; 3(11):351-8. PMC: 3224868. DOI: 10.4330/wjc.v3.i11.351. View